MindMaze Theraputics
+ Menu
  • Solutions
    • MindMaze platform
      • Our approach
      • Clinical evidence
    • Therapy & monitoring
      • Companion
      • MindMotion GO
      • MindPod
      • Izar
      • Physilog
      • ToapRun
    • Drug development
      • Relief Therapeutics pipeline and portfolio
  • Research & Innovation
    • MindMaze Labs
      • Neurotherapeutics frontiers
      • Research collaborations
      • Human performance
      • Deep technology
  • Investor relations
    • Share price
    • Board & executive team
    • Key stock information
    • Financial reports
    • Articles of association
    • US ADR Program
    • Financial calendar
    • News and Events
    • Shareholder’s general meeting
    • Equity research coverage
    • Investor presentations
    • Investor newsletter
  • About
    • MindMaze Therapeutics
    • Media
    • Careers
    • Testimonials
    • Contact
MindMaze Theralputics
+ Menu
  • Solutions
    • MindMaze platform
      • Our approach
      • Clinical evidence
    • Therapy & monitoring
      • Companion
      • MindMotion GO
      • MindPod
      • Izar
      • Physilog
      • ToapRun
    • Drug development
      • Relief Therapeutics pipeline and portfolio
  • Research & Innovation
    • MindMaze Labs
      • Neurotherapeutics frontiers
      • Research collaborations
      • Human performance
      • Deep technology
  • Investor relations
    • Share price
    • Board & executive team
    • Key stock information
    • Financial reports
    • Articles of association
    • US ADR Program
    • Financial calendar
    • News and Events
    • Shareholder’s general meeting
    • Equity research coverage
    • Investor presentations
    • Investor newsletter
  • About
    • MindMaze Therapeutics
    • Media
    • Careers
    • Testimonials
    • Contact
Investor relations

Financial reports

2025

2025 Half-year Report | 2024 Annual Report

2024

2024 Half-year Report | 2023 Annual Report

2023

2023 Half-year Report | 2022 Annual Report

2022

2022 Half-year Report | 2021 Annual Report

2021

2021 Half-year Report | 2020 Annual Report

2020

2020 Half-year Report | 2019 Annual Report

Chemin de Roseneck 5
1006 Lausanne, Switzerland

+41 21 552 08 01
info@mindmaze.com
  • MindMaze platform
  • Therapy & monitoring
  • Drug development
  • Research & innovation
  • Investor relations
  • About
  • Contact
copyright © 2025 | terms and conditions | EU privacy policy | U.S. privacy policy | PERSONAL DATA REQUESTS
We value your privacy
We use cookies to enhance your browsing experience and analyze our traffic. By clicking "I accept", you consent to our use of cookies.